September 2, 2015

VolitionRx to Present at Rodman & Renshaw 17th Annual Global Investment Conference in New York and CNAPS IX Conference in Berlin on September 9 and 11, 2015

Presentations to include the first full data from VolitionRx's 4,800-subject blinded independent retrospective colorectal cancer blood diagnostic study

NAMUR, Belgium, Sept. 2, 2015 /PRNewswire/ --VolitionRx Limited (NYSE MKT: VNRX), a life sciences company focused on developing blood-based diagnostic tests for a broad range of cancer types and other conditions, today announced that its Chief Executive Officer, Cameron Reynolds, is scheduled to present at the 17th Annual Rodman & Renshaw Global Investment Conference being held September 8-10, 2015 in New York, NY. In addition, VolitionRx's Business Development Director, Dr. Mark Eccleston will be presenting at the CNAPS (Circulating Nucleic Acids in Plasma and Serum) IX Conference being held September 10-12 in Berlin, Germany. These conferences are attended by public companies, institutional investors, industry executives, scientists, private equity firms, private companies, venture capitalists, business development executives and sophisticated private investors.

During their respective presentations, Mr. Reynolds and Dr. Eccleston will discuss top-line results from VolitionRx's 4,800-subject retrospective colorectal cancer blood diagnostic study at Hvidovre Hospital, Denmark. Mr. Reynolds' presentation will also outline VolitionRx's business milestones and growth strategy. Following his presentation, Dr. Eccleston will participate in a panel discussion, 'Academia meets industry: Future and unmet needs in liquid biopsy'.

Details of the presentations are as follows:

Conference:	Rodman & Renshaw 17th Annual Global Investment Conference
Date:	Wednesday, September 9, 2015
Time:	1:45 p.m. EDT
Location:	Louis XVI at the St. Regis Hotel in New York

Conference:	CNAPS IX, Industrial Session
Date:	Friday, September 11, 2015
Time:	3:05-3:25 p.m. CEST (Panel discussion 5:30-7:00 p.m. CEST)
Location:	Saphir Room at Andel´s Hotel in Berlin

Persons attending the Rodman & Renshaw conference who would like to schedule a 1-on-1 meeting with VolitionRx management during the conference may do so by contacting Lee

Roth or Joseph Green of The Ruth Group at lroth@theruthgroup.com or jgreen@theruthgroup.com.

For those unable to attend, a live webcast of Mr. Reynolds' presentation will be available at http://wsw.com/webcast/rrshq25/vnrx. Following his presentation, this webcast will be archived for 90 days.

About VolitionRx

VolitionRx is a life sciences company focused on developing blood-based diagnostic tests for different types of cancer. The tests are based on the science of Nucleosomics which is the practice of identifying and measuring nucleosomes in the bloodstream – an indication that cancer is present.

VolitionRx's goal is to make the tests as common and simple to use, for both patients and doctors, as existing diabetic and cholesterol blood tests. VolitionRx's research and development activities are currently centred in Belgium as the company focuses on bringing its diagnostic products to market first in Europe, then in the US and ultimately, worldwide.

Visit VolitionRx's newly redesigned website (www.volitionrx.com) or connect with us on Twitter, LinkedIn, Facebook or YouTube.

Media Contacts

Anita Heward, VolitionRx
a.heward@volitionrx.com
Telephone: +44 (0) 7756 034243

Kirsten Thomas, The Ruth Group
kthomas@theruthgroup.com
Telephone: +1 (646) 536-7014

Investor Contacts

Scott Powell, VolitionRx
S.Powell@volitionrx.com
Telephone: +1 (646) 650-1351

Lee Roth, The Ruth Group
lroth@theruthgroup.com
Telephone: +1 (646) 536-7012

Safe Harbor Statement

Statements in this press release may be "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, that concern matters that involve risks and uncertainties that could cause actual results to differ materially from those anticipated or projected in the forward-looking statements. Words such as "expects," "anticipates," "intends," "plans," "aims," "targets," "believes," "seeks," "estimates," "optimizing," "potential," "goal," "suggests" and similar expressions identify forward-looking statements. These forward-looking

statements relate to the effectiveness of the Company's bodily-fluid-based diagnostic tests as well as the Company's ability to develop and successfully commercialize such test platforms for early detection of cancer. The Company's actual results may differ materially from those indicated in these forward-looking statements due to numerous risks and uncertainties. For instance, if we fail to develop and commercialize diagnostic products, we may be unable to execute our plan of operations. Other risks and uncertainties include the Company's failure to obtain necessary regulatory clearances or approvals to distribute and market future products in the clinical IVD market; a failure by the marketplace to accept the products in the Company's development pipeline or any other diagnostic products the Company might develop; the Company will face fierce competition and the Company's intended products may become obsolete due to the highly competitive nature of the diagnostics market and its rapid technological change; and other risks identified in the Company's most recent Annual Report on Form 10-K and Quarterly Report on Form 10-Q, as well as other documents that the Company files with the Securities and Exchange Commission. These statements are based on current expectations, estimates and projections about the Company's business based, in part, on assumptions made by management. These statements are not guarantees of future performance and involve risks, uncertainties and assumptions that are difficult to predict. Forward-looking statements are made as of the date of this release, and, except as required by law, the Company does not undertake an obligation to update its forward-looking statements to reflect future events or circumstances.

Nucleosomics®, NuQ® and HyperGenomics® and their respective logos are trademarks and/or service marks of VolitionRx Limited and its subsidiaries. All other trademarks, service marks and trade names referred to in this prospectus are the property of their respective owners.

To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/volitionrx-to-present-at-rodman--renshaw-17th-annual-global-investment-conference-in-new-york-and-cnaps-ix-conference-in-berlin-on-september-9-and-11-2015-300136770.html

SOURCE VolitionRx Ltd